Roche Strikes Obesity Drug Licensing Deal Worth up to $1.16 Billion with Chinese Rona Therapeutics
- On Tuesday, Swiss drugmaker Roche entered a licensing agreement worth up to $1.16 billion with Rona Therapeutics for its investigational obesity drug candidate, ALK7.
- Seeking to challenge the market dominance of Eli Lilly and Novo Nordisk, Roche aims to leverage Rona's proprietary RNAi platform to develop novel metabolic therapies.
- The deal provides Rona with an upfront payment of $100 million, while the firm remains eligible for up to $1.06 billion in potential milestone payments and tiered royalties.
- CEO and Founder Stella Shi called ALK7 a "compelling obesity and metabolic disease target" with potential to selectively reduce visceral fat while preserving lean mass.
- Unlike therapies working in the CNS, ALK7 inhibition acts directly on adipose tissue biology, creating potential for independent use or combination with established obesity treatments.
13 Articles
13 Articles
Roche has concluded an agreement with the Chinese Rona Therapeutics to license the global rights of an experimental therapy against obesity and metabolic diseases for up to $1.16 billion. Exclusive material for subscribers. To have full access, access the link of the material and register.
With the partnership, the pharmaceutical group secures a worldwide license for active ingredients against obesity. This pushes Roche further to the lucrative market for weight loss preparations.
PR Newswire
The QueenslanderRona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases
/PRNewswire/ -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational...
Roundup: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy, Enodia Therapeutics Enters Collaboration and License Agreement to Develop Sec61-Targeting Small Molecules
Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics on Sec61 inhibitor discovery.
Coverage Details
Bias Distribution
- 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
